Two High-Risk Prostate Cancer Treatments Have Similar Benefits, Add-On Study Finds

Two High-Risk Prostate Cancer Treatments Have Similar Benefits, Add-On Study Finds
Two treatment approaches — Zytiga (abiraterone acetate) plus prednisolone (AAP) or Taxotere (docetaxel) — provided patients with high-risk prostate cancer similar benefits when added to standard hormone deprivation therapy, according to data recently presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain. While progression-free survival and other short-term measures slightly favored AAP, there was no difference in overall survival among patients treated with the two approaches. This leaves it up to oncologists to decide which treatment to opt for, researchers said, a decision that will likely be guided by availability and patient preferences. The study, “Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): directly randomised data from STAMPEDE (NCT00268476),” used data gathered in a Phase 2/3 trial called STAMPEDE. In contrast to most other trials — which only compare a few treatments — this study includes six treatment approaches, of which some include several drugs. The therapies are compared to standard of care — androgen deprivation therapy — in patients with high-risk prostate cancer. Some patients also received radiotherapy as part of their standard regimen. All patients were newly diagnosed. “Right now, oncologists and urologists want to know which combination is preferable, which is why we conducted this analysis,” Matthew Sydes, statistician, MRC Clinical Trials Unit at
Subscribe or to access all post and page content.